Skip to Content

Cabotegravir Injection Can Protect Women From HIV for Two Months

MONDAY, Nov. 9, 2020 -- An experimental injection drug works better than daily pills to protect women from getting HIV from an infected sex partner, researchers say.

The drug cabotegravir is given every two months. It was 89 percent more effective at preventing HIV infection than Truvada pills, but both reduced the risk, the Associated Press reported. The study, which took place in Africa, was stopped early due to the promising results. The new findings echo those announced earlier this year from a study that compared the shots against the daily pills in gay men, the AP reported.

"This is a major, major advance," according to Anthony Fauci, M.D., the top infectious disease doctor at the U.S. National Institutes of Health. "I don't think we can overemphasize the importance of this study."

Young women may be two times more likely than men to get HIV in some areas of the world, said one of the study leaders, Sinead Delany-Moretlwe, M.B.B.Ch., Ph.D., of the University of the Witwatersrand in Johannesburg, South Africa, the AP reported.

AP News Article

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Kidney Disease May Add to Higher Risk for CVD Due to HIV

FRIDAY, Dec. 18, 2020 -- Kidney function has a strong influence on the effect of HIV serostatus on brachial artery flow-mediated dilation (FMD), a measure of endothelial function,...

WHO: Strawberry-Flavored HIV Medication Coming for Infants

TUESDAY, Dec. 1, 2020 -- A strawberry-flavored version of the first-line HIV medication dolutegravir will soon be available for infants. The medication will come in a tablet that...

Recommendations Updated for HIV Treatment, Prevention

MONDAY, Oct. 26, 2020 -- In a 2020 guideline from the International Antiviral Society-USA, published online Oct. 14 in the Journal of the American Medical Association, updated...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.